Skip to main content
58°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Lineage Cell Therapeutics, Inc.
< Previous
1
2
3
Next >
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
August 01, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
July 02, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at 2024 BIO International Convention
May 30, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
May 21, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
May 06, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
May 02, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Changes to Board of Directors
April 29, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
April 30, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
February 29, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
April 01, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
February 09, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
March 18, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
February 06, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
March 13, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
March 11, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
February 13, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
November 01, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
January 16, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
December 18, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
October 24, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
October 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
September 19, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
October 05, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
September 13, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
September 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
September 06, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Tickers
LCTX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.